BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH’s RECOVER-TLC Third Annual Workshop
BioVie was invited to present Phase 2 ADDRESS-LC data on bezisterim in Long COVID at the NIH RECOVER-TLC workshop on November 5, 2026. The release recaps that the trial showed consistent trends toward improvement, with statistically significant gains only in pre-specified subgroups with severe baseline fatigue, PEM, or cognitive impairment; the overall intent-to-treat population missed significance on all endpoints.
Key figures
- Drug Name
- bezisterim (NE3107)
- Phase Of Trial
- Phase 2
- Dose
- 20 mg oral capsule twice daily
- Trial enrollment
- 203
- Dow award amount usd
- 13130000
- Subgroup symptom prevalence
- approximately 78% of trial participants in at least one domain
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.